| Literature DB >> 35452491 |
Marie Couturier1, Mélanie Touvrey-Loiodice1, Nicolas Terrapon2, Elodie Drula2,3, Laurine Buon1, Christine Chirat4, Bernard Henrissat5,6, William Helbert1.
Abstract
β-Mannans are a heterogeneous group of polysaccharides with a common main chain of β-1,4-linked mannopyranoside residues. The cleavage of β-mannan chains is catalyzed by glycoside hydrolases called β-mannanases. In the CAZy database, β-mannanases are grouped by sequence similarity in families GH5, GH26, GH113 and GH134. Family GH113 has been under-explored so far with six enzymes characterized, all from the Firmicutes phylum. We undertook the functional characterization of 14 enzymes from a selection of 31 covering the diversity of the family GH113. Our observations suggest that GH113 is a family with specificity towards mannans, with variations in the product profiles and modes of action. We were able to assign mannanase and mannosidase activities to four out of the five clades of the family, increasing by 200% the number of characterized GH113 members, and expanding the toolbox for fine-tuning of mannooligosaccharides.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35452491 PMCID: PMC9032380 DOI: 10.1371/journal.pone.0267509
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Phylogenetic tree of family GH113.
Enzymes studied here are shown with red symbols: filled dots indicate that an activity was assigned to the enzyme, empty ones indicate that no activity could be demonstrated. Stars indicate that the target protein was not obtained in a soluble form. Enzymes characterized in previous studies are labeled in grey. A high-resolution phylogenetic tree is available in Supplementary Material, S1 Fig.
List of enzymes studied in this work, their characteristics and qualitative activities on mannan substrates.
| Strains | GenBank | SigP | Sol | GlcM | GalM | M | Oligo-M | Mode of action |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| AHF90006.1 | N | - | na | na | na | na | ||
|
| CCO05952.1 | N | + | + | + | + (M2) | nd | Endo |
| ADL53106.1 | N | + | + | + | + (M2) | nd | Endo | |
| AFC30869.1 | N | + | + | + | + (M2) | nd | Endo | |
| AFC29300.1 | N | + | + | + | + (M2) | nd | Endo | |
|
| AIQ63165.1 | N | + | - | - | - | + (M2+M1) | Exo |
| AIQ46016.1 | N | + | - | - | - | + (M2+M1) | Exo | |
| AGY82530.1 | N | + | - | - | - | + (M2+M1) | Exo | |
| AJA57161.1 | N | + | - | - | - | - | ||
| EDP22100.1 | N | + | - | - | (+) | + (M2+M1) | Exo | |
| CBK82649.1 | N | + | + | + | + | nd | Endo | |
| AGF59019.1 | N | + | - | - | - | + (M2+M1) | Exo | |
| ABG77968.1 | Endo* | |||||||
| AGN12833.1 | Endo* | |||||||
| BAM48369.1 | Endo* | |||||||
| AML27062.1 | Endo* | |||||||
| CBL01979.1 | Exo* | |||||||
| VCV21219.1 | Exo* | |||||||
|
| ||||||||
| ACG77425.1 | N | + | - | - | - | - | ||
| AAM39996.1 | Y | + | + | + | + (M3+M4) | nd | Endo | |
| AJZ27962.1 | Y | + | + | + | + (M3+M4) | nd | Endo | |
|
| ||||||||
|
| BAL60159.1 | N | + | - | - | + (M3+M4) | nd | Endo |
| CCK30803.1 | N | + | - | - | - | - | ||
| EAR94190.1 | Y | - | na | na | na | na | ||
| CBW26415.1 | N | - | na | na | na | na | ||
|
| ||||||||
| ACB07175.1 | Y | + | + | + | + (M3+M4) | nd | Endo | |
|
| BAL57546.1 | Y | + | - | - | - | - | |
|
| ||||||||
| ABC45350.1 | N | - | na | na | na | na | ||
| ALW87438.1 | N | + | - | - | - | - | ||
| SDR82740.1 | N | - | na | na | na | na | ||
|
| CCG00503.1 | Y | + | - | - | - | - | |
| EAR00501.1 | Y | + | - | - | - | - | ||
| EAQ39091.1 | Y | + | - | - | - | - | ||
| EAS20280.1 | Y | + | - | - | - | - | ||
|
| AOW18367.1 | Y | + | - | - | - | - | |
| CDF78977.1 | Y | + | - | - | - | - | ||
| CCH01584.1 | N | - | na | na | na | na |
Main end-products are given into brackets for linear polysaccharides. SigP: Signal peptide (Y for predicted; N otherwise). Sol: Expression of soluble proteins. Substrates: + for degradation of the substrate; (+) for a weak degradation and—for no degradation. nd: not detected. na: not applicable
*: results from previous works. Underlined GenBank accession numbers highlight sequences for which the 3D structure was solved.
(GlcM: Glucomannan, M: β (1,4) mannan, GalM: galactomannan, OligoM: Oligo-mannans).
Fig 2Analysis of the endo mode of action of two GH113 representatives.
The degradation of debranched β 1,4 mannan by A: CCO05952 (Clade 1) and B: AJZ27962 (Clade 2) was monitored using size-exclusion chromatography. M2: mannobiose, M3: mannotriose, M4: mannotetraose.
Fig 3Analysis of the exo mode of action of five GH113 Clade 1 representatives.
A: The degradation of mannohexaose (M6) by EDP22100 was monitored by HPAEC-PAD. B: Analysis of end-products released by AGY82530, AGF59019, AIQ46016 and AIQ63165 after overnight incubation with M6. M1: Mannose, M2: mannobiose, M3: mannotriose, M6: mannohexaose.
Specific activity of representatives of M1+ M2 producing enzymes (AJZ27962.1, Clade 1) and M3+M4 producing enzymes (CCO05952.1, Clade 2) towards mannans.
| Specific activity (U/mg) | ||
|---|---|---|
| AJZ27962.1 | CCO05952.1 | |
| Konjac glucomannan (0% Gal, mannose:glucose = 60:40) | 9.39 +/-0.51 | 3.00 +/-0.30 |
| Carob linear β-1,4 mannan (0% Gal) | 4.73 +/-0.64 | 3.35 +/-0.0 |
| Carob galactomannan (22% Gal) | 4.14 +/-0.45 | 3.04 +/-0.0 |
| Guar gum (50% Gal) | 0.89 +/-0.34 | 2.79 +/-0.59 |